MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202641113879 A) filed by Dr. R. Sivakumar; Neeraja Podichety; and Dr. V Sridevi Vakkant on September 23, 2026, for Novel Approach To Narcolepsy Management: Polysomnography-Guided Diagnosis With Pitolisant, Solriamfetol, And Emerging Orexin-Based Therapy.
Inventors include Dr. R. Sivakumar; Neeraja Podichety; and Dr. V Sridevi Vakkant.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: The most commonly reported adverse effects — headache, nausea, decreased appetite, insomnia, and anxiety— tend to emerge within the first two weeks of therapy and often resolve within a similar timeframe. Because solriamfetol raises dopamine and norepinephrine tone, cardiovascular parameters such as blood pressure and hd.rt-fate warrant periodic-monitoring particularly in-patients-with-pre-existing-hypertension_oncardiac disease; dedicated QT-interval studies have not shown a clinically important effect on cardiac repolarization at therapeutic doses. In practice, solriamfetol is frequently chosen as initial therapy for EDS without cataplexy, as a replacement when modafinil, armodafinil, or pitolisant are ineffective or poorly tolerated, or as an add-on agent when EDS remains only partially controlled on another wake-promoting drug or on sodium oxybate. Clinically, virtually all patients report EDS, often described as an irrepressible urge to sleep during monotonous activities, unrefreshing daytime naps, or outright "sleep attacks." Beyond EDS, patients frequently describe chronic fatigue, memory or concentration difficulties, and impaired performance at school, at work, or while driving. The Epworth Sleepiness Scale (ESS), a simple self-report questionnaire, is widely used in clinic to quantify subjective sleepiness and to track response to treatment over time, complementing the objective measures obtained on PSG and MSLT.Cataplexy, present in narcolepsy type 1, is often the most functionally disruptive and diagnostically specific symptom. Episodes range from subtle jaw or neck weakness to complete postural collapse, are typically triggered by laughter, surprise, or anger, and resolve within seconds to a couple of minutes without loss of consciousness. Sleep paralysis and hypnagogic hallucinations, while less specific to narcolepsy, further reflect the intrusion of REM-sleep physiology into wakefulness and are frequently reported alongside EDS
Disclaimer: Curated by HT Syndication.
